Suzhou Basecare Medical (HKG:2170) obtained approval for the renewal of the registration certificate of its PGT-A kit for five years from China's National Medical Products Administration in October, a Wednesday bourse filing said.
The renewed registration certificate is valid till Feb. 20, 2030.
The PGT-A kit is used to accurately detect the DNA of blastocyst trophoblast cells and analyze the potential existence of any abnormalities of aneuploidy in embryos.
Shares of the genetic technology researching company closed nearly 10% higher on Wednesday.
Price (HKD): $2.81, Change: $+0.25, Percent Change: +9.77%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。